Copyright
©The Author(s) 2023.
World J Transplant. Dec 18, 2023; 13(6): 368-378
Published online Dec 18, 2023. doi: 10.5500/wjt.v13.i6.368
Published online Dec 18, 2023. doi: 10.5500/wjt.v13.i6.368
Table 3 Primary and secondary efficacy endpoints
| Non-expressers (n = 15) | Intermediate metabolizer (n = 13) | Extensive metabolizer (n = 6) | P value | |
| Time (d) to therapeutic tacrolimus concentration, median (IQR) | 4.5 (1.0-7.0) | 6.0 (4.0-11.5) | 13.5 (7.5-20.25) | 0.025 |
| Tacrolimus dose (mg) at therapeutic concentration, median (IQR) | 12 (10-14) | 16 (13-20) | 16 (11-20.5) | 0.010 |
| Weight-based tacrolimus dose (mg/kg) at therapeutic concentration, median (IQR) | 0.13 (0.12-0.165) | 0.20 (0.125-0.25) | 0.19 (0.138-0.265) | 0.018 |
| Tacrolimus dose (mg), median (IQR) | 9.6 (9.2-10.1) | 12.5 (10.6-14.5) | 13.8 (10.4-14.4) | 0.011 |
| Weight-based tacrolimus dose (mg/kg), median (IQR) | 0.128 (0.102-0.142) | 0.136 (0.108-0.169) | 0.176 (0.128-0.217) | 0.074 |
| Tacrolimus trough concentration (ng/mL), mean ± SD | 10.78 ± 2.1 | 9.18 ± 1.6 | 7.98 ± 1.3 | 0.008 |
| Weight-based tacrolimus dose at day 30 (mg/kg), mean ± SD | 0.103 ± 0.429 | 0.154 ± 0.620 | 0.167 ± 0.590 | 0.022 |
| Potassium (mEq/L), mean ± SD | 4.29 ± 0.36 | 4.68 ± 0.35 | 4.35 ± 0.59 | 0.041 |
| Serum creatinine (mg/dL) at day 30, median (IQR) | 1.76 (1.29-2.62) | 1.75 (1.27-2.65) | 1.94 (1.2-3.0) | 0.906 |
| eGFR (mL/min/1.73 m2) at day 30, median (IQR) | 40.0 (27.0-58.0) | 46.0 (30.0-58.5) | 31.5 (25.0-56.3) | 0.701 |
- Citation: Diamond A, Karhadkar S, Chavin K, Constantinescu S, Lau KN, Perez-Leal O, Mohrien K, Sifontis N, Di Carlo A. Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype. World J Transplant 2023; 13(6): 368-378
- URL: https://www.wjgnet.com/2220-3230/full/v13/i6/368.htm
- DOI: https://dx.doi.org/10.5500/wjt.v13.i6.368